Impact of SARS-CoV-2 infection in patients with cardiac amyloidosis: Results of a multicentre registry.

Fecha de publicación: 06/09/2023 Fecha Ahead of Print: 06/09/2023

Autores de IIS La Fe

Francisco Domínguez Hernández

Autor
Esther Zorio Grima

Autor

Participantes ajenos a IIS La Fe

Larrañaga-Moreira JM
Rodriguez-Serrano AI
Lalario A
Barriales-Villa R
Dilemma International Cardiomyopathy, Heart Failure Registry Investigators Group

Grupos

Biología Reproductiva y Bioingeniería en Reproducción Humana

Leader

Nicolás Garrido Puchalt
Cardiopatías familiares, muerte súbita y mecanismos de enfermedad (CAFAMUSME)

Investigador Principal

Aitana Braza Boils

Abstract

BACKGROUND: Descriptions on impact of SARS-CoV-2 infection in patients with cardiac amyloidosis (CA) are lacking. Our aim was to describe the prognosis of those patients. METHODS: Retrospective observational study of unvaccinated patients with CA who developed SARS-CoV-2 infection enrolled in eleven centres (March 2020 to May 2021). Descriptive analysis of basal characteristics, hospitalization, mortality, and severe clinical course was performed. Comparisons to a population-based control group were made. RESULTS: Forty-one patients were identified. Most patients had wild-type transthyretin CA (61%) and were on NYHA Class II-III (80.5%). CA patients were commonly hospitalized (73.2%) and those were more symptomatic than outpatients (p=0.035). The 24.4% of CA patients died as consequence of SARS-CoV-2 infection. Patients with CA had an increased risk of hospitalization [OR 6.23 (3.05-12.74), p<0.001] and mortality [OR 2.18 (1.01-4.68), p=0.047] when compared to control population after adjustment by age and sex. After a medium follow-time of 311 days, 41.5% of the CA cohort died. CONCLUSIONS: SARS-CoV-2 infection is associated with high mortality and hospitalization rates in patients with CA, which exceed that expected by their sex and advanced age.

Datos de la publicación

ISSN/ISSNe:: 0025-7753, 1578-8989
Tipo:: Article
Páginas:: 476-482
DOI:: 10.1016/j.medcli.2023.06.025
Factor de Impacto:: 0,325 SCImago ℠
Cuartil:: Q3 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Larrañaga-Moreira JM:: Unidad de Cardiopatías Familiares, Instituto de Investigación Biomédica de A Coruña (INIBIC), Hospital Universitario de A Coruña (HUAC), Servizo Galego de Saúde (SERGAS), Universidade da Coruña (UDC), A Coruña, Spain. Electronic address:
Domínguez F:: Unidad Cardiopatias Familiares, Hospital Universitario Puerta Hierro Majadahonda, IDIPHISA, Madrid, Spain

Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain
Lalario A:: Cardiovascular Department 'Ospedali Riuniti' and University of Trieste, Trieste, Italy
Zorio E:: Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain

Unidad Cardiopatías Familiares, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Instituto de Investigación. Instituto de Investigación Sanitaria La Fe, Valencia, Spain
Barriales-Villa R:: Unidad de Cardiopatías Familiares, Instituto de Investigación Biomédica de A Coruña (INIBIC), Hospital Universitario de A Coruña (HUAC), Servizo Galego de Saúde (SERGAS), Universidade da Coruña (UDC), A Coruña, Spain

Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain

Keywords

Amiloidosis cardíaca; COVID-19; Cardiac amyloidosis; Heart failure; Infección por SARS-CoV-2; Insuficiencia cardíaca; Prognosis; Pronóstico; Registries; Registro; SARS-CoV-2 infection

Campos de estudio

Proyectos asociados

RED INVESTIGACION (RECAVA)

RD06/0014/0004 . INSTITUTO DE SALUD CARLOS III; FUNDACION PARA LA INV BIOMEDICA- HOSPITAL GREGORIO MARAÑON; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006